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Abstract
Cardiovascular disease (CVD) is the Nation's leading killer for both men and women among all
racial and ethnic groups. Development and progression of CVD is linked to the presence of risk
factors such as hyperlipidemia, hypertension, obesity, and diabetes mellitus. It is known that
cholesterol is an indicator of increased risk of heart attack and stroke. Low-density cholesterol
(LDL) above 130 mg/dl high-density cholesterol (HDL) cholesterol below 35 mg/dl and total blood
cholesterol above 200 mg/dl are indicators of problematic cholesterol. Proper ranges of
cholesterol are important in the prevention of CVD.
It has been suggested that a reduction in the consumption of saturated and an increase in
unsaturated fatty acids is beneficial and prevents CVD. Amaranth grain contains tocotrienols and
squalene compounds, which are known to affect cholesterol biosynthesis. The cholesterol
precursors squalene, lanosterol and other methyl sterols, reflect cholesterol synthesis [1-3],
whereas plant sterols and cholestanol, a metabolite of cholesterol, reflect the efficiency of
cholesterol absorption in normal and hyperlipidemic populations [4-6].
Qureshi with co-authors [7] showed that feeding of chickens with amaranth oil decreases blood
cholesterol levels, which are supported by the work of others [8]. Previously, we have shown that
Amaranth oil modulates the cell membrane fluidity [9] and stabilized membranes that could be one
reason as to why it is beneficial to those who consume it. It is known that in hypertension, the cell
membrane is defective and hence, the movement of the Na and K ions across the cell membranes
could defective that could contribute to the development of increase in blood pressure. Based on
these properties of amaranth oil we hypothesize that it could be of significant benefit for patients
with CVD.
Background
Amaranth is defined as a "never-fading flower" in Greek.
Various Amaranthus species were grown by the Aztecs
5,000 to 6,000 years ago, prior to the disruption of the
South American civilization by the Spanish conquista-
dors. Both the grain amaranth and leaves are utilized for
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use for human as well as for animal food [10]. The nutri-
tional value of amaranth has been extensively studied [11-
14]. Grain amaranth has higher protein than other cereal
grains and has significantly higher lysine content [15,16].
It has been shown that amaranth leaves are an excellent
source of protein, with its maximal accumulation in the
blossoming phase [17] (17.2–32.6% from dry weight for
varius samples).
Amaranth grain consists of 6 to 9% of oil which is higher
than most other cereals. Amaranth oil contains approxi-
mately 77% unsaturated fatty acids and is high in linoleic
acid, which is necessary for human nutrition. The lipid
fraction is unique due to the high squalene content.
Detailed studies on amaranth grain oil have been
researched further in the last 2–3 decades [18-21]. Vegeta-
ble amaranth has received significantly less research atten-
tion than grain amaranth. However, it has been rated
considerably higher in minerals, such as calcium, iron,
phosphorous [22,23] and caretonoids [24] than most veg-
etables. Pharmacological properties of different amaranth
species also have been investigated. It was determined
that Amaranth paniculatus and Amaranth cruentus are
good sources of flavanoids, especially for rutin, which are
mostly produced in the stage of blossoming [25]. Usage of
amaranth as livestock feed indicated relatively high pro-
tein qualities [26-28].
The vital issue with the future of amaranth can be deter-
mined by the end-use product. Since 1991, we are work-
ing on vegetable and grain amaranth commercialization
by formulating and producing new amaranth products
especially for the prevention and treatment of cardiovas-
cular diseases such as coronary heart disease and hyper-
tension. Our investigation indicated that amaranth grain
is a good source of modern diet, particularly to make spe-
cial products for the people who are at a high risk to car-
diovascular diseases [29]. Furthermore, new formulas
were created on the base of natural ingredients only with
amaranth flour, containing a significant amount of mag-
nesium and dietary fiber. This is extremely beneficial for
people who have high blood pressure and are at a high
risk of cardiovascular diseases such as heart attack [30].
Coronary heart disease is the most common cause of mor-
tality. Risk factors for CVD include: hyperlipidemia,
hypertension, obesity, and glucose intolerance. Several
studies revealed that a reduction in blood pressure
reduces the risk and incidence of CVD [31,32].
Studies clearly established that decreased consumption of
saturated and trans fats is of significant benefit to those
who have hypertension. In this context, it important to
mention that consumption of products with low content
of animal fat and increased use of unsaturated fats are of
benefit in hypertension and may reduce the risk of CVD.
Amaranth oil can lower cholesterol in animal models in
view of its rich content of squalene and polyunsaturated
fatty acids. This is supported by the observation that ham-
sters which received hypercholesterolemic diets and were
given Amaranth oil (5%), they experienced a decrease in
total and non-high-density lipoprotein cholesterol by 15
and 22%, respectively, in comparison to the control group
[33]. In the presented study, we investigated the effects of
amaranth oil in patients suffering from coronary heart dis-
ease (CHD) and hypertension (HP) with obesity.
Methods and materials
The effect of amaranth oil was studied in a randomized
placebo-controlled clinical trial of 125 patients with CVD.
The patients were randomized to amaranth oil (3 ml ama-
ranth oil provides a 100 mg squalene) 3–18 ml amaranth
oil daily. All 125 patients got similar dietary and behavio-
ral recommendations and low-salt diet. Biochemical and
clinical indices was monitored during the treatment and
after 3 weeks. The experiment was conducted on men and
women, aged 32–68, suffering from coronary heart dis-
ease and hypertension accompanied by obesity. The fol-
lowing exclusion criteria were used:
1.Those having been affected with stroke, myocardial inf-
arction, coronary angioplasty or having undergone an
operation of aortocoronary shunting three months prior
to the investigation.
2.Diagnosis of acute coronary deficiency three months
prior to the investigation.
3.Renal insufficiency or liver failure.
4.The presence of acute or aggravated chronic diseases.
Eighty patients (85 people in the main group and 40 peo-
ple in the group of comparison) suffering from coronary
heart disease and hypertension in the 1st and 2nd stages
accompanied by obesity of the 1st and 3rd stages were
under observation.
All the patients received a reduced hyposodium antiather-
ogenic diet (HAD). The test group of patients received 3,
6, 12 and 18 ml. of amaranth oil instead of the sunflower
oil. The control group received only the HAD.
Amaranth oil has been extracted from the Amaranthus
hybridus L. (Amaranthaceae). Amaranth oil was applied
in four doses by 3 ml. (100 mg squalene – 25% adequate
level of consumption), 6 ml. (200 mg), 12 ml. (400 mg. –
100%) and 18 ml. (600 mg. – 150%) per day.Lipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
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The overall duration of the clinical trial was 3 weeks. All
the patients received a traditional course of treatment,
which included the hyposodium antiatherogenic diet,
exercise, and hydro and procedures. The test group and
the control group were made of patients suffering from
coronary heart disease and hypertension of the 1st and 2nd
stages. A thorough medical examination was conducted.
An electrocardiogram (ECG) and echocardiogram were
conducted for the verification of the diagnosis. All
patients in the test group were closely followed for any
possible side effects due to the consumption of amaranth
oil. Their organoleptic properties and tolerance were eval-
uated based on the availability and intensity of side effects
as a result of the intake of the product. The clinical trials
were conducted on the following groups of patients:
The patients of the comparison group – 40 people (2 male
and 38 females) suffering from CHD and HP (average age
was 52.4 years old). The patients of the first main group –
25 people (5 males and 20 females) suffering from CHD
and HP (average age was 59.4 years old). They got a ration
where 20 g sunflower oil have been replaced by amaranth
oil and corn oil. The amount of squalene in this mix was
100 mg per a day. The patients of the second main group
(200 mg squalene/day) – 20 patients (2 males and 18
females) suffering from CHD and HP (average age was
46.6 years old). The patients of the third main group (400
mg squalene/day) – 20 patients (3 males and 17 females)
suffering from CHD and HP (average age was 59.2 years
old). The patients of the forth main group (600 mg
squalene/day) – 20 patients (3 males and 17 females) suf-
fering from CHD and HP (average age was 59.2 years old).
Description of Hyposodium Antiatherogenic Diet
The hyposodium antiatherogenic diet (HAD) is character-
ized by its low content of calories, small amounts of salt
and fat, refined carbohydrates, cholesterol-containing
products and extracted substances. The protein content in
the ration corresponds to the physiological standard. It
includes products containing lipotropic substances, poly-
unsaturated fatty acids, and food fibers. The description of
the HAD diet is described below in Table 1.
Clinical methods of investigation
An integrated checkup of the patients in the Clinic
included the study of signs for diseases such as: blood
Table 1: Chemical Composition of HAD and Rations including Amaranth Oil
Indices HAD Amaranth Oil
(3 g/day)
Amaranth Oil
(6 g/day)
Amaranth Oil
(12 g/day)
Amaranth Oil
(18 g/day)
P r o t e i n s ,  g 7 5 7 57 57 57 5
F a t s ,  g 6 0 6 06 06 06 0
Carbohydrates, g 190 190 190 190 190
Caloricity, kcal 1600 1600 1600 1600 1600
Fatty acids:
Unsaturated fatty acids 22.831 23.217 23.502 24.173 24.844
C 14:0 5.054 5.062 5.065 5.076 5.087
C 15:0 0.164 0.164 0.172 0.18 0.188
C 16:0 11.844 12.646 12.523 13.202 13.881
C 17:0 0.288 0.318 0.35 0.412 0.474
C 18:0 5.062 4.682 5.007 4.952 4.897
C 20:0 0.231 0.297 0.222 0.213 0.204
C 22:0 0.188 0.048 0.163 0.138 0.113
Monounsaturated fatty acids, g 21.423 22.515 21.285 21.147 21.009
C 14:1 0.455 0.455 0.455 0.455 0.455
C 16:1 1.852 1.879 1.86 1.868 1.876
C 17:1 0.008 0.008 0.008 0.008 0.008
C 18:1 18.707 19.708 18.515 18.323 18.131
C 20:1 0.207 0.241 0.253 0.299 0.345
C 22:1 0.194 0.224 0.194 0.194 0.194
Polyunsaturated fatty acids 15.129 13.724 14.32 13.511 12.702
C 18:2 13.424 11.761 12.560 11.696 10.832
C 18:3 0.275 0.533 0.330 0.385 0.440
C 18:4 0.015 0.015 0.015 0.015 0.015
C 20:4 0.355 0.355 0.355 0.355 0.355
C 20:5 0.042 0.042 0.042 0.042 0.042
C 22:5 0.902 0.902 0.902 0.902 0.902
C 22:6 0.116 0.116 0.116 0.116 0.116
PUFAs ω-6/PUFAs ω-3 10.2 7.533 9.192 8.254 7.384
∑ PUFAs ω-3 1.575 1.608 1.405 1.460 1.515Lipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
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arterial pressure (BAP) level, heartbeat rate (HBR), EKG
data, and the evaluation of organoleptic properties and
tolerance to oil.
Biochemical methods of investigation
The biochemical indices were determined by means of the
"SPECTRUM" analyzer (ABBOTT, USA). The content of
low-density cholesterol in the blood serum, very low-den-
sity cholesterol (VLDL), and atherogenic coefficient value
(AC) were evaluated in the rated manner.
VLDL = TG/2.2
LDL = Total Cholesterol - TG/2.2 - HDL
AC = (Total Cholesterol - HDL)/HDL
The statistical treatment of the results was recorded in
EXCEL, and was expressed as M ± m. The significant level
of the revealed differences was determined by using Stu-
dent's t-criteria.
Results and discussion
The amaranth oil was extracted by press methods and the
following physical and chemical characteristics were
determined. The results are shown in Table 2.
It is known that amaranth grain contains 6 to 10% oil,
which is mostly within the germ [34-36]. Amaranth oil is
predominantly an unsaturated oil (76%) and is high in
linoleic acid, which is necessary for human nutrition.
Yanez E. with coauthors [37] showed that oil extracted
from Amaranthus cruentus contained 19% palmitic acid,
3.4% stearic acid, 34% oleic acid and 33% linoleic acid.
Docosaenoic acid (C22: 1) was present at the level of 9%.
The ratio of saturated to unsaturated fatty acids was
approximately 1:3. We provided an extraction of ama-
ranth oil by press methods for the experiments. The fatty
acid composition of amaranth oil was determined, which
is provided in Table 3.
The investigation of He HP and others has shown that the
major fatty acids in Amaranth oil consist of palmitic acid
(19.1–23.4%), oleic acid (18.7–38.9%), and linoleic acid
(36.7–55.9%) [38]. The food and energy values of ama-
ranth oil are shown in Table 4. As you can see, amaranth
oil received by the press method has a great amount of
squalene and tocopherols. It is known that squalene is an
intermediate metabolite in the synthesis of cholesterol.
Supplementation of squalene to mice has resulted in
marked increases in cellular and non-specific immune
functions in a dose-dependent manner [39]. Experimental
evidence suggests that 90 percent of the newly formed
squalene is stored in the lipid droplet and only 10 percent
is used in cholesterol synthesis [40].
Evaluation of organoleptic properties and tolerance of 
amaranth oil
Based on a standard procedure, an extended testing of
amaranth oil was made. The evaluation of its organoleptic
properties and tolerance was conducted based on a fill-in-
the-blank method. The organoleptic properties were eval-
uated based on 5 parameters of a five-score system. In
addition, the tolerance of the oil was tested. The results
received are presented in Tables 5 and 6 below.
As can be seen in Table 5, the overwhelming majority of
patients (over 80%) highly enjoyed (put the highest score
for) the oil quality. Much emphasis was made on its ben-
eficial organoleptic properties. Pleasant outward appear-
ances, homogeneous consistence and the absence of
foreign inclusions were also established. The properties of
the amaranth oil met the required standards. A growing
number of the patients placed a lot of emphasis on its
amiable taste.
The percents indicate the number of people polled. None
of the participants taking part in the testing mentioned an
unpleasant "aftertaste". As can be seen in Table 6, the tol-
erance of amaranth oil was good. Throughout the clinical
trials, no single case of intolerance, dyspepsia occurrences,
allergic reactions or other side effects were established.
Upon the completion of the clinical trials, all of the
patients expressed their willingness to continue the intake
of the certified amaranth oil under house conditions.
It has been reported that a combination of fish oil supple-
mentation and salt restriction is highly effective in lower-
Table 2: Physico-Chemical Characteristics Of Amaranth Oil
Physico-Chemical Characteristics Characteristics of Amaranth Oil
Iodine number, mg 130
Acid number, mg KOH/g, 2.9
Mass fraction of the non fat admixtures in % 0.2
Mass fraction of the phosphor containing substances in P2O5%0 . 1
Mass fraction of moisture and volatile substances, % 0.1
Peroxide number, mmole/kg of active oxygen 2.4Lipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
Page 5 of 12
(page number not for citation purposes)
ing systolic and diastolic blood pressure [41]. After four
weeks the mean systolic blood pressure had decreased by
8.9 mm Hg and the diastolic pressure by 6.0 mm Hg.
The researchers concluded that sodium restriction com-
bined with fish oil supplementation lowered blood pres-
sure in elderly people with normal blood pressure. It has
been shown that supplementation with 7.7 to 9 grams/
day of fish oil will reduce systolic blood pressure by 4 mm
Hg and diastolic pressure by 3 mm Hg in hypertensive
individuals [42]. Table 7 shows how the systolic blood
pressure decreased with the amaranth oil treatment com-
bined with the HAD.
The weight loss for the control group and the group of
patients with an amaranth diet did not have a big differ-
ence. The weight loss was about 5.1–6.5%, which is
related to the HAD.
Evaluation of the dynamics of the clinical indices during 
diet therapy with the inclusion of amaranth oil
The diet therapy with amaranth oil contributed to the
decrease or disappearance of headaches, weakness,
increased fatigability, shortness of breath during a physi-
cal activity, edema of legs toward the evening hours and
feeling of intermission of heart function in most patients.
The positive dynamics on electrocardiograms were
observed in 40–50% of patients and were displayed by
rhythm normalization (disappearance of sinus tachycar-
dia, bradycardia, single ventricular and supraventricular
extrasystole), decrease in the intensity of the signs of cor-
onary deficiency (which was evident by the change in the
interval S-T and wave T).
Results given in Table 7 shows that the level of systolic
arterial pressure was decreased by 18%, 19%, and 21% in
the course of the treatment in patients of the 1st , 2nd and
3rd of the main group and the groups of comparison – by
18%, diastolic – by 14%, 15%, 19% and by 17%. In addi-
tion, heart rate in the course of the treatment tended to
decrease in patients of all the groups.
The degree of decrease in excess body weight in the course
of the treatment of the patients in the main groups and
the groups of comparison amounted to 6.5%, 6.2%, 5.1%
and 6.1%. The average daily loss of body weight for the
patients of the main groups and the groups of comparison
was equal to 304 g, 348 g, 219 g and 271 g, accordingly.
Evaluation of the dynamics of biochemical indices during 
diet therapy with the inclusion of amaranth oil
It is known that there is a correlation between diet and
cholesterol level in blood serum. Alpha-linolenic acid
(ALA), omega-3 fatty acid, found in large amounts in flax-
seed oil is not effective in lowering triglyceride levels, a
risk factor for heart disease [43]. A group of researchers
conducted a study in people with a history of heart dis-
ease, using the Mediterranean diet [44]. The Mediterra-
nean diet included a special margarine high in alpha-
Table 5: Value Of Amaranth Oil's Organoleptic Properties
Indices Number of Scores Amaranth Oil
Outward Appearance 5
4
100%
0
Odor 5
4
83%
17%
Color 5
4
98%
0
Taste 5
4
92%
8%
Consistence 5
4
100%
0
Table 4: Food and Energy Value of 100 g Amaranth Oil
Food value Amaranth Oil
Triglycerides (g) 78
Squalene (g) 5.9
Phospholipids (g) 8
Phytosterols (g) 2
Sum of tocopherols (vitamin E), in mg 300
Carotinoids (mg) 0.5
Energy value, kcal/kJ 711/87
Table 3: Fatty Acid Composition of Amaranth Oil
Fatty acids
(Shorthand designation)
Mass Fraction of Fatty Acids (in %)
Press methods Chemical extraction
14:0 0.14 0.15
15:0 0.15 0.08
16:0 19.19 18.59
16:1 0.13 0.08
17:0 1.05 1.37
18:0 3.38 4.45
18:1 22.64 22.69
18:2 49.89 48.00
18:3ω6 0.35 0.35
18:3ω3 1.01 0.92
20:0 0.16 0.27
20:1 1.04 1.49
22:0 0.32 0.24
24:0 0.05 0.08
22:1 0.07 0.7
24:1 0.43 0.54Lipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
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linolenic acid. Those people assigned to the Mediterra-
nean diet had a 70% reduced risk of dying from cardiovas-
cular diseases compared with the control group during the
27 months. Similar results were reported by others as well
[45]. Nevertheless, the success of the Mediterranean diet
does not prove that ALA protects against heart disease
[46]. The influence of an antisclerotic diet with a sour-
milk product enriched with an extract of leaves of an ama-
ranth in patients with ischemic heart disease and hyper-
tension was investigated by Zoblkova ZS and coauthors
[47]. As a result of the diet with extracts of amaranth leafs
were positive dynamic of clinic manifestation and lipid
spectrum of blood.
It is evident from Table 8 that inclusion of amaranth oil in
the HAD contributed to a statistically significant decrease
in the total cholesterol level in the blood serum in
patients of the 1st , 2nd and 3rd of the main groups and the
groups of comparison, accordingly, by 14%, 17%, 20%
and 12% and triglycerides and VLDL Cholesterol – by
13%, 21%, 36% and 16%, LDL – by 19%, 23%, 25% and
12%, the value of atherogenic ratio – by 18%, 23%, 32%
and 8%. The contents in the blood serum HDL in patients
of the 3rd main group had a tendency towards increase, in
the main groups it virtually remained unchanged, and in
the group of comparison it decreased by 9%. The level of
the remaining investigated biochemical indices changed
to the same degree in the patients of the main groups and
the group of comparison. It is known, that low HDL cho-
lesterol and high LDL cholesterol are more specifically
linked to cardiovascular disease than is total cholesterol
[48].
The link between high triglyceride levels and cardiovascu-
lar diseases is not as well established as the link between
high cholesterol and heart disease. But, according to some
studies, a high triglyceride level is an independent risk fac-
tor for cardiovascular diseases in some people [49].
It is known that squalene is involved in cholesterol syn-
thesis, but it is not clear yet squalene's role in the process
of lowering the cholesterol amount in blood serum. Even
more, dietary supplementation with one gram of squalene
daily for nine weeks was reported to cause increases in
VLDL and LDL-cholesterol concentrations by 34 and 12
percent, respectively. However, a subsequent six-week
period on a lower dose of squalene dietary supplementa-
tion (0.5 g/day) normalized serum sterols [50].
Evaluation of fatty-acid composition of cell membrane in 
patients with coronary heart disease and hypertension
Studies have shown that replacing saturated fat with
unsaturated fat in the diet can help lower blood pressure.
For example, Fish oils containing eicosapentaenoic acid
Table 7: Dynamics of Clinical Characteristics under the Effects of Diet and Amaranth Oil
Clinical Attributes HAD Amaranth Oil
3 g (100 mg 
squalene per day)
Amaranth Oil
6 g (200 mg 
squalene per day)
Amaranth Oil 
12 g (400 mg 
squalene per day)
Amaranth Oil 
18 g (600 mg 
squalene per day)
Systolic Blood Pressure (mm Hg) 1 146 ± 2.13 143 ± 7.58 142 ± 2.48 149 ± 2.42 144 ± 1.13
2 121 ± 2.08** 118 ± 2.28** 116 ± 2.92** 120.6 ± 1.40** 114 ± 1.12**
Diastolic Blood Pressure (mm Hg)* 1 96.8 ± 2.59 87.5 ± 3.61 98.1 ± 1.01 97.5 ± 2.13 89.0 ± 2.01
2 82 ± 1.8* 76.7 ± 1.36* 85.2 ± 1.86** 80.9 ± 0.8** 72.0 ± 2.11**
Frequency of Heart Contraction (hit/min) 1 82.2 ± 2.50 76.2 ± 2.8 78.2 ± 2.23 78.8 ± 2.13 79.4 ± 2.15
2 69.3 ± 2.92 68 ± 2.7 67.4 ± 2.94 68.0 ± 2.17 78.3 ± 2.02
Weight (kg) 1 93.4 ± 2.51 85.9 ± 4.138 97.9 ± 3.98 117.9 ± 4.66 91.3 ± 3.14
2 87.7 ± 1.98 81.2 ± 3.28 91.5 ± 3.82 110.6 ± 3.40 86.7 ± 1.03
1 – Before Treatment, 2 – After Treatment
Table 6: Evaluation Of Tolerance Of Amaranth Oil
Indices Amaranth Oil 3 g
(100 mg squalene per day)
Amaranth Oil 6 g
(200 mg squalene per day)
Amaranth Oil 12 g
(400 mg squalene per day)
Amaranth Oil 18 g 
600 mg squalene per day)
E r u c t a t i o n 0000
N a u s e a 0000
H e a r t b u r n 0000
Bitter taste in mouth 0000
P a i n s  i n  t h e  a b d o m e n 0000
A l l e r g i c  r e a c t i o n s 0000Lipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
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(EPA) and docosahexaenoic acid (DHA) have been found
more effective in lowering triglyceride levels and blood
pressure [51].
The analysis of the fatty acid composition of erythrocyte
membrane of patients was conducted based on a tradi-
tional method of gas-liquid chromatography. The investi-
gation results are presented in Table 9 below.
The treatment based on a basic diet along with the inclu-
sion of amaranth oil brought about a dose-dependant
action in respect to oleic acid (18:1), the content of which
increased to the maximum (by 16%) when using a 6 ml
of amaranth per day. The concentration of linoleic (18:2)
and linolenic acids (18:3) decreased in the course of diet
therapy in patients of all the groups. Along with this, a
dose-dependant action in respect to a long chain polyun-
saturated fatty acid of omega family 3 – docosapentaenoic
(22:5) and docosahexaenoate (22:6) was established. If
the concentration of these acids in erythrocyte mem-
branes decreased in patients suffering from coronary heart
disease and hypertension who received a diet with a con-
tent of 6 ml of amaranth oil per day, then the concentra-
tion of erythrocyte membranes increased by 9% and 18%
in patients of the 2nd main group and by 9% and 28% in
patients of the 3rd main group.
The total increase in membranes polyunsaturated fatty
acids was evident only in patients of the 3rd main group.
Simultaneously, in the course of diet therapy a maximal
decrease of part unsaturated fatty acids in erythrocyte
membranes.
Hence, changes in the fatty-acid composition of erythro-
cyte membranes under the influence of various doses of
amaranth oil are evident and were only expressive when
using 18 ml of oil on a daily basis. Apparently, the
observed clinical effects were related not only to the
change in fatty-acid composition of diet, but also the
squalene content in it.
Estimation of the antioxidant action of amaranth oil in 
patients with CVD
Antioxidants are important components of nutrition
which prevent the formation of free radicals, inhibit them
or participate in their destruction process, help to avoid
oxidative stress, and provide protection from chronic dis-
eases [52].
Amaranth grain and its oil fraction have antioxidative
effect on streptozotocin-induced diebetic rats.53  The
authors suggest that amaranth grain and amaranth oil
supplements, as an antioxidant therapy, may be beneficial
for correcting hyperglycemia. However, there are not
enough investigations about amaranth oil antioxidant
properties specifically for humans. Below are the results of
our study about amaranth oil antioxidant properties for
humans.
As can be seen in Table 10, the enrichment of food ration
by amaranth oil had an essential positive effect on the per-
oxide oxidation of lipids – antioxidant protection (POL -
AP), manifesting by reduction in the products of the per-
oxide oxidation of lipids (diene conjugates and the
malonic dialdehyde of plasma) and by growth of the fer-
ments of antioxidant protection (glutathione reductase
(GR), glutathionperoxidase(GP), superoxidedismutase
(SODM), catalase(CAT).
Thus, in particular, the diet therapy resulted in the reduc-
tion in the diene conjugates of plasma (DC) and of
malonic dialdehyde (MDA) in the basic groups of patients
Table 8: Dynamics of biochemical characteristics of patients under the effects of diet and amaranth oil
Biochemical Sings HAD Amaranth Oil
3 g (100 mg squalene 
per day)
Amaranth Oil
6 g (200 mg squalene 
per day)
Amaranth Oil
12 g (400 mg 
squalene per day)
Amaranth Oil
18 g (600 mg 
squalene per day)
Total cholesterol mmol/L 1 6.31 ± 0.23 7.06 ± 0.6 5.58 ± 0.23 5.76 ± 0.23 6.60 ± 0.23
2 5.57 ± 0.20* 5.69 ± 0.3* 4.79 ± 0.20* 4.76 ± 0.20* 5.29 ± 0.20*
Triglycerides mmol/L 1 1.34 ± 0.13 1.57 ± 0.2 1.88 ± 0.13 1.17 ± 0.13 2.49 ± 0.13
2 1.13 ± 0.10 1.45 ± 0.18 1.62 ± 0.10 0.93 ± 0.10 1.58 ± 0.10
HDL Cholesterol mmol/L 1 1.65 ± 0.11 1.66 ± 0.32 1.16 ± 0.11 1.26 ± 0.11 1.15 ± 0.11
2 1.51 ± 0.07 1.42 ± 0.22 1.13 ± 0.07 1.24 ± 0.07 1.19 ± 0.07
LDL Cholesterol mmol/L 1 4.03 ± 0.20 4.69 ± 0.44 3.90 ± 0.20 3.74 ± 0.20 4.42 ± 0.20
2 3.54 ± 0.17 3.61 ± 0.26 3.18 ± 0.17 2.89 ± 0.17 3.32 ± 0.17
VLDL Cholesterol mmol/L 1 0.61 ± 0.06 0.71 ± 0.09 0.99 ± 0.06 0.58 ± 0.06 1.25 ± 0.06
2 0.51 ± 0.04 0.66 ± 0.08 0.81 ± 0.04 0.46 ± 0.04 0.79 ± 0.04
Aterogenic Index (AI) 1 3.15 ± 0.27 3.65 ± 0.41 4.06 ± 0.27 3.80 ± 0.27 5.21 ± 0.27
2 2.90 ± 0.25 3.47 ± 0.44 3.33 ± 0.25 2.98 ± 0.25 3.54 ± 0.25
1 – Before Treatment, 2 – After Treatment
AI = (Total Cholesterol - HDL): HDL under p < 0.05; ** under p < 0.01.Lipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
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Table 9: The effect of amaranth oil on fatty-acid composition of erythrocyte membrane of patients
Fatty Acids HAD Amaranth Oil
3 g (100 mg 
squalene per day)
Amaranth Oil
6 g (200 mg 
squalene per day)
Amaranth Oil 
12 g (400 mg 
squalene per day)
Amaranth Oil 
18 g (600 mg 
squalene per day)
12:0 1 -- 0.35 1.14 1.22 1.07
2 -- 0.34 0.57 1.26 0.90
14:0 1 2.02 5.2 2.18 2.23 2.19
2 1.44 4.11 0.97 2.89 1.99
15:0 1 2.9 2.28 0.61 0.62 0.77
2 2.08 2.29 0.44 0.76 0.72
16:0 1 15.9 24.99 15.4 18.44 19.6
2 17.75 16.1 23.0 16.40 17.8
16:1 1 3.98 4.68 0.88 1.09 1.30
2 2.87 6.04 0.82 2.91 1.44
17:0:1 1 3.28 5.04 1.11 1.27 1.41
2 2.55 2.87 1.07 1.27 1.41
18:0 1 12.81 8.22 11.70 12.45 12.24
2 11.55 11.29 14.78 11.15 12.15
18:1 1 14.29 20.4 14.05 14.95 14.85
2 14.93 17.76 15.43 15.09 17.17
18:2 1 8.48 9.65 11.05 11.61 11.57
2 9.96 10.78 12.67 11.13 10.74
18:3 1 1.7 0.57 0.40 0.69 0.52
2 0.88 0.8 0.11 0.19 0.26
20:0 1 -- 0.22 0.57 0.45 0.63
2 -- 0.2 0.33 0.49 0.34
20:1 1 -- 0.66 0.84 0.79 0.96
2 -- 1.07 0.61 0.95 0.81
20:2 1 -- 0.63 0.51 0.43
2 -- 0.35 0.55 0.56
20:3 1 1.64 1.66 2.53 1.96 2.17
2 1.16 1.31 1.50 1.57 2.22
20:4 1 15.03 5.77 15.33 13.66 11.7
2 14.95 10.93 14.04 14.75 14.15
20:5 1 1.45 2.05 4.06 4.64 3.80
2 1.03 4.23 1.08 3.00 2.40
22:1 1 -- 0.83 2.75 2.80 3.82
2 -- 1.5 1.89 3.00 3.14
22:4 1 5.4 1.71 0.52 0.53 0.54
2 5.65 1.27 0.83 0.50 0.46
24:0 1 3.55 0.18 0.23 0.19 0.18
2 4.51 0.22 0.18 0.22 0.22
22:5 1 2.6 1.0 2.91 2.13 2.05
2 2.32 1.31 1.77 2.30 2.22
22:6 1 5.42 2.46 9.40 6.99 6.45
2 6.41 4.1 7.10 8.26 8.05
24:1 1 -- 0.73 1.10 0.84 0.94
2 -- 0.63 0.94 1.00 1.02
Sum of omega 3 1 11.17 6.08 16.77 14.31 12.88
2 10.64 10.44 10.23 13.75 12.37
Sum of PUFAs 1 50.2 25.82 46.83 42.59 39.43
2 42.36 35.5 38.94 42.26 40.56
Sum of UFAs 1 37.18 47.03 31.83 35.6 36.68
2 37.33 34.55 40.27 33.17 34.12
1 – Before Treatment, 2 – After Treatment
PUFAs – Polyunsaturated fatty acids
UFAs – Unsaturated fatty acidsLipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
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respectively to 17–29% and 21–46%, accordingly. In the
patients of the comparison group, the reduction in the
data of indices composed 9% and 12%.
It is noted also the considerable growth of the ferments of
antioxidant protection proportional to the concentration
of amaranth oil in the diet. In this case, the greatest
dynamics are fixed in a change in the levels of glutathione
reductase (GR) and of catalase (CAT) in basic groups to
12%, 47%, 42%, 21% and 11%, 26%, 8%, 37%, and in
the patients of the group of comparison to 10% and 23%,
accordingly.
The estimation of the immunomodulating action of 
amaranth oil in patients with ischemic heart diseases and 
hyperlipidemia
Humoral immunity has been suggested to play an impor-
tant role in the diseases for both adults and children, but
the function of neutralizing antibody responses in delay-
ing disease progression has not been fully established [54-
58].
The results of investigating the indices of humoral immu-
nity are given in Table 11.
According to the immunogram, the levels of IgM and IgG
content in the blood serum of patients before treatment
and after treatment was within the norm (0,5–2,0 g/l for
IgM; 5,3–16,5 g/l for IgG).
It is known that Il-1β appears cytokin of the wide spec-
trum of action, produced predominantly by macrophages.
It causes the starting reactions of immunity and plays a
key role in the development of inflammation. Il-1β also
plays one of the central roles in the inflammatory reac-
Table 11: Dynamics of the Indices of Humoral Immunity in Patients with Ischemic Heart Diseases and hyperlipidemia under the effect 
of the basic therapy with the application amaranth oil (M ± m)
Indices HAD Amaranth Oil
3 g (100 mg squalene 
per day)
Amaranth Oil
6 g (200 mg squalene 
per day)
Amaranth Oil
12 g (400 mg squalene 
per day)
Amaranth Oil
18 g (600 mg squalene 
per day)
IgM, mg/ml 1 0.79 ± 0.07 0.81 ± 0.07 2.25 ± 0.96 1.82 ± 0.78 1.0 ± 0.33
2 0.73 ± 0.03 0.87 ± 0.06 2.43 ± 1.04 1.98 ± 0.78 1.2 ± 0.21
IgG, mg/ml 1 4.32 ± 0.37 4.33 ± 0.97 8.25 ± 0.45 5.56 ± 1.86 11.28 ± 1.76
2 4.45 ± 0.7 5.63 ± 0.1 10.23 ± 3.89 7.33 ± 2.66 15.27 ± 0.13
IL-4, pg/ml 1 13.7 ± 2.8 8.91 ± 1.9 15.0 ± 3.3 7.67 ± 2.19 12.75 ± 4.66
2 15.64 ± 2.2 11.0 ± 3.2 17.78 ± 5.79 12 ± 3.22 16.5 ± 2.51
IL-1β, pg/ml 1 173.9 ± 20.97 186.4 ± 25.3 8.0 ± 1.41 4.0 ± 1.22 4.32 ± 1.16
2 150.7 ± 19.52 112.6 ± 21.32 4.62 ± 1.53 2.84 ± 1.02 2.38 ± 0.06
1 – Before Treatment, 2 – After Treatment
Table 10: Dynamics of the indices of POL – AP system in Patients with Ischemic Heart Diseases and Hyperlipidemia (M ± m)
Indices HAD Amaranth Oil
3 g (100 mg squalene 
per day)
Amaranth Oil
6 g (200 mg squalene 
per day)
Amaranth Oil
12 g (400 mg squalene 
per day)
Amaranth Oil
18 g (600 mg squalene 
per day)
DC, nmole/ml 1 4.12 ± 0.34 4.98 ± 0.39 5.71 ± 0.77 5.35 ± 1.05 5.49 ± 0.49
2 3.75 ± 0.29 4.13 ± 0.27 4.06 ± 0.42 5.07 ± 0.71 5.45 ± 0.81
MDA, nmole/ml 1 3.02 ± 0.17 4.4 ± 0.28 2.37 ± 0.34 2.688 ± 0.39 2.5 ± 0.49
2 2.66 ± 0.08 3.38 ± 0.19 1.27 ± 0.12 2.118 ± 0.36 2.49 ± 0.49
GP, micromole/min/ml 1 20.6 ± 0.62 22.3 ± 3.77 23.4 ± 3.43 26.2 ± 1.61 24.1 ± 4.16
2 20.4 ± 0.51 22.6 ± 3.61 23.88 ± 4.45 28.5 ± 0.99 22.4 ± 0.78
GR, micromole/min/ml 1 1.81 ± 0.14 1.77 ± 0.1 1.158 ± 0.42 0.57 ± 0.1 1.31 ± 0.18
2 1.97 ± 0.09 1.98 ± 0.27 1.7 ± 0.98 0.8 ± 0.34 1.58 ± 0.74
SODM nominal units/ml 1 2816 ± 160 1826 ± 42.4 2112 ± 83.96 1991 ± 34.63 1998 ± 43.1
2 3098 ± 148 1810 ± 26.3 2365 ± 77.12 2267,8 ± 70.0 2338 ± 100
CAT, kU/ml 1 183 ± 11.3 203 ± 33.3 223 ± 23.53 226 ± 17.23 178 ± 37.88
2 226 ± 9.93 225 ± 25.8 281.8 ± 20.87 208.8 ± 4.2 244 ± 30.66
1 – Before Treatment, 2 – After Treatment
Diene Conjugates (DC), Malonic Dialdehyde (MDA), Peroxide Oxidation of Lipids – Antioxidant Protection (POL -AP), Glutathione Reductase 
(GR), Superoxidedismutase (SODM), catalase (CAT).Lipids in Health and Disease 2007, 6:1 http://www.lipidworld.com/content/6/1/1
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tion, in response to the bacterial infection and the tissue
damages.
Raising the level of Il-1β is observed with different inflam-
matory and autoimmune diseases, including cardiovascu-
lar pathology. Statistically reliable reduction of its content
in the blood serum in patients, who had an amaranth oil
intake, contained respectively 100, 200, 400 and 600 mg
of squalene (to 39%, 42%, 28% and 45%) and an
improvement in the clinical state of patients. Further-
more, patients who had a standard diet intake had a 14%
reduction.
The level of free fraction Il-4 in the blood serum of
patients who consumed amaranth oil exceeded initially to
26%. After the course of treatment, there was an increase
in the content of cytokin in the blood serum of patients
who consumed amaranth oil, contained 100, 200, 400
and 600 mg of squalene, accordingly to 24%, 19%, 57%
and 29% (r<0,05). Furthermore, patients who had a
standard diet intake had a 14% reduction. As primary tar-
gets, Il-4 serves B-lymphocytes for which it is the strongest
growth factor. In other words, there was an improvement
in the humoral immunity of patients. It was then estab-
lished that amaranth oil possesses high biological activity.
This is true because amaranth oil contains 77% of polyun-
saturated fatty acids, from which 50% comprises the lino-
leic acid. Furthermore, amaranth oil is characterized by
the high content of such biologically active compounds,
such as: squalene (up to 8%), tocopherols (to 2%), phos-
pholipids (to 10%), and phytosterols (to 2%). A good ger-
micidal action is established, and also the high
regeneration and antitumorigenic properties of amaranth
oil. Amaranth oil increases the antioxidant and immu-
nomodulating property of HAD.
In conclusion, the results of the present study shows that
amaranth oil can reduce the amount of cholesterol in
blood serum, and it can be recommended as a functional
food product for the prevention and treatment of cardio-
vascular diseases. Diet with amaranth oil may help reduce
blood pressure and could serve as an effective alternative
to drug therapy in people with hypertension. This investi-
gation also showed that a combination of amaranth oil
with a hyposodium antiatherogenic diet is more effective
to reduce the amount of blood cholesterol than just the
hyposodium antiatherogenic diet. The next step of our
investigation is to study mechanism of cholesterol lower-
ing properties of amaranth oil. Squalene as well as phyto-
sterolls can be involved in that mechanism. As you can see
on the Table 4 amaranth oil contains great amount of
phytosterols, which are chemical homologs of choles-
terol. Phytosterols interfere with the micellar solubiliza-
tion of cholesterol in the intestine and reduce the
efficiency of cholesterol absorption [59].
Conclusion
1. The inclusion of amaranth oil in the diet has a benefi-
cial action upon the clinical presentation of Coronary
Heart Disease and Hypertension. Its beneficial action is
seen best when used at a dose of 18 ml per day.
2. Amaranth oil decreases the amount of total cholesterol,
triglycerides, LDL and VLDL significantly. The concentra-
tion-dependent cholesterol lowering effect of characteriz-
ing amaranth oil has been proven.
3. The inclusion of amaranth oil in the diet contributes to
an increase in the concentration of polyunsaturated fatty
acids, particularly, long-chain acid of omega 3 families in
patients suffering from hypertension and coronary heart
disease.
4. Our studies indicate that Amaranth oil can be consid-
ered as an effective natural antioxidant supplement capa-
ble of protecting cellular membranes against oxidative
damage.
Abbreviations
Hyposodium Antiatherogenic Diet (HAD), Atherogenic
Coefficient value (AC), Diene Conjugates (DC), Malonic
Dialdehyde (MDA), Peroxide Oxidation of Lipids – Anti-
oxidant Protection (POL -AP), Glutathione Reductase
(GR), Superoxidedismutase(SODM), Catalase(CAT),
Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid
(DHA), PUFAs – Polyunsaturated Fatty Acids, UFAs –
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